Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Wigen Biomedicine Technology (Shanghai) Co. Ltd. currently manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct examiners and 5 distinct art units. This one-to-one ratio between pending actions and examiners indicates a highly fragmented prosecution landscape where each matter is reviewed by a different individual.
The busiest examiner for the portfolio is KUCHARCZK, JED A, who is responsible for 1 pending office action. Because the total number of pending office actions is 5 and there are 5 distinct examiners, the workload is perfectly balanced across the assigned staff. This lack of concentration means the company must navigate the specific preferences of 5 different examiners without a single dominant point of contact.
Furthermore, the presence of 5 distinct art units for 5 pending actions indicates that the company's biotechnology innovations are being classified into several specialized sub-sectors. Practitioners should prepare for varied examination styles across these 5 distinct art units, as no single unit dominates the current pending queue. This distribution highlights the technical diversity of the company's active patent applications in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCHARCZK, JED A | 1 | 80.4% | +16.3% |
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039229 | NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION COMPRISING SAME AND USE THEREOF | DEKARSKE, MADELINE MCGUIRE | 13d |
| 18845669 | KIF18A INHIBITOR | KUCHARCZK, JED A | — |
| 18838598 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | RAO, SAVITHA M | — |
| 18706531 | COMPOUNDS USED AS SRC INHIBITORS | MAHLUM, JONATHAN DAVIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039229 | NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION COMPRISING SAME AND USE THEREOF | DEKARSKE, MADELINE MCGUIRE | 13d |
| 18845669 | KIF18A INHIBITOR | KUCHARCZK, JED A | — |
| 18838598 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | RAO, SAVITHA M | — |
| 18706531 | COMPOUNDS USED AS SRC INHIBITORS | MAHLUM, JONATHAN DAVIS | — |
| 18578384 | NAPHTHYRIDINE DERIVATIVE AS ATR INHIBITOR AND METHOD FOR PREPARING SAME | NOTTINGHAM, KYLE GREGORY | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1691 | 1 |
| 1625 | 1 |
| 1621 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18845669 | KIF18A INHIBITOR | KUCHARCZK, JED A | 1623 | §102§112 | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18838598 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | RAO, SAVITHA M | 1691 | §101§112 | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18706531 | COMPOUNDS USED AS SRC INHIBITORS | MAHLUM, JONATHAN DAVIS | 1625 | §103§112 | Non-Final OA | — | Pending | May 01, 2024 |
| 18578384 | NAPHTHYRIDINE DERIVATIVE AS ATR INHIBITOR AND METHOD FOR PREPARING SAME | NOTTINGHAM, KYLE GREGORY | 1621 | §103 | Final Rejection | — | Pending | Jan 11, 2024 |
| 18039229 | NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION COMPRISING SAME AND USE THEREOF | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Final Rejection | 13d | Pending | May 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWigen Biomedicine Technology (Shanghai) Co. Ltd. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Jed A Kucharczk has the most, with 1 of Wigen Biomedicine Technology (Shanghai) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
